Article

Amacrine cells: key players in growth regulation in the eye

The development and maintenance of emmetropia is largely controlledlocally by the retina. This is accomplished by detecting andsignaling whether images are in or out of focus hyperopically ormyopically. The amacrine cells are most likely the key players ofgrowth regulation, said William Stell, PhD, MD.

The development and maintenance of emmetropia is largely controlled locally by the retina. This is accomplished by detecting and signaling whether images are in or out of focus hyperopically or myopically. The amacrine cells are most likely the key players of growth regulation, said William Stell, PhD, MD.

"The amacrine cells play critical roles in the processing of focus-defocus information by which growth is controlled," said Dr. Stell, of the University of Calgary, Alberta, Canada. "Photoreceptor-horizontal-bipolar cell assemblies provide amacrine cells with the means to do this, but are unlikely to signal focusing or defocusing directly."

The roles of dopamine and acetylcholine in the signaling process of the amacrine cells have been studied extensively, but glucagon is considered the key candidate for the focus-defocus messenger in chick retinas. Glucagon, however, has not been demonstrated or eliminated as having that role in mammalian retinas.

"What is unknown is where glucagon acts," he said. There are at least two pathways through which glucagon acts: one direct and one indirect.

"The rate of axial elongation of the eye is regulated visually by feedback to optimize the vision," Dr. Stell said. "The mechanisms are in the retina. The amacrine cell-derived messenger must regulate scleral growth and choroidal thickness via the retinal pigment epithelium (RPE).

"However, the effects of the RPE and the RPE-derived messenger that act upon the choroids and sclera are not yet known," Dr. Stell concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.